Adenylyl cyclase

Adenylyl cyclase (also called adenylate cyclase or adenyl cyclase) is an enzyme embedded in the cell membrane that converts adenosine triphosphate (ATP) into cyclic AMP (cAMP) — a small signaling molecule that relays a receptor's message into the interior of the cell. Many receptors cannot cross the membrane themselves; adenylyl cyclase is one of the principal bridges that turns surface-level activation into a coordinated intracellular response.

Multiple isoforms exist throughout the body. Several are concentrated in the brain, with high expression in regions involved in pain, reward, and stress — areas where the enzyme's activity is directly shaped by opioids, cannabinoids, and other psychoactive substances.

How it works · its role

Adenylyl cyclase is regulated by G proteins — the molecular intermediaries that translate receptor activation into changes inside the cell. Receptors coupled to Gs proteins activate the enzyme, raising intracellular cAMP; receptors coupled to Gi/o proteins inhibit it, lowering cAMP.

The level of cAMP determines how active protein kinase A (PKA) is — an enzyme that goes on to phosphorylate ion channels, transcription factors, and many other proteins throughout the cell. A fall in cAMP therefore cascades outward: it reduces neuronal excitability, damps down neurotransmitter release, and quiets a wide array of downstream processes simultaneously.

Relevance to substances & effects

Opioid receptors — mu, kappa, and delta subtypes — are among the most prominent inhibitors of adenylyl cyclase in the brain. When opioids bind these receptors, the resulting drop in cAMP contributes to pain suppression, sedation, and the blunted stress response that characterises opioid action across the class.

Cannabinoid CB1 receptors share this Gi/o coupling and suppress adenylyl cyclase similarly — part of the mechanistic overlap between cannabis and opioids in pain modulation. Dopamine's D2-family receptors also inhibit the enzyme, while D1 and D5 receptors activate it; this balance underpins reward signaling relevant to stimulant pharmacology and the mechanism of action of antipsychotics.

Alpha-2 adrenergic agonists such as clonidine also suppress adenylyl cyclase through Gi/o coupling, which partly accounts for their use in managing opioid withdrawal symptoms.

Tolerance & dependence

Sustained inhibition of adenylyl cyclase prompts neurons to compensate: cAMP signaling components are upregulated over days and weeks — a process known as adenylyl cyclase superactivation. While the inhibiting drug is present this adaptation is largely invisible; the system has simply recalibrated around a new baseline.

When the drug is removed, the now-overtuned machinery produces a cAMP surge. In opioid dependence, that rebound contributes directly to withdrawal: agitation, heightened pain sensitivity, anxiety, and autonomic instability are in part expressions of excess cAMP activity. The same compensatory upregulation underlies tolerance development — repeated receptor activation progressively blunts the downstream effect per dose.